The combination of lapatinib, trastuzumab, and an AI highlighted a PFS improvement versus trastuzumab plus an AI (mPFS was 11 vs. 5.6 months; hazard ratio = 0.62; p = 0.0063) in postmenopausal patients HR-positive/HER2-positive advanced BC previously treated with ET and trastuzumab plus CT in the neo(adjuvant) and/or first-line metastatic setting [69]. The gene discussed is ERBB2; the disease is breast cancer.